Phase 3 results have a high probability of Success · Strong Phase 2 Foundation: In the Phase 2 trial, the 50 mg dose (the dose used in Phase 3) achieved an 81% reduction in mean monthly attacks (Weeks 5–16) and a 77% reduction overall. · Complete Response Rate: Perhaps most importantly for your "functional cure" assessment, 73% of Phase 2 patients (8 out of 11) in the 50 mg arm were completely attack-free through the primary observation period.Read more